Press release
Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Chronic Urticaria Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Urticaria Pipeline Outlook [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Chronic Urticaria Pipeline Report
* In July 2025, Novartis Pharmaceuticals announced a study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
* DelveInsight's Chronic Urticaria Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Urticaria treatment.
* The leading Chronic Urticaria Companies such as Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.
* Promising Chronic Urticaria Pipeline Therapies such as Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine , and others.
Stay ahead with the most recent pipeline outlook for Chronic Urticaria. Get insights into clinical trials, emerging therapies, and leading companies with Chronic Urticaria @ Chronic Urticaria Treatment Drugs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Urticaria Emerging Drugs Profile
* CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
CMAB007 is a recombinant humanized anti-IgE monoclonal antibody developed by Taizhou Mabtech Pharmaceutical Co., Ltd., a subsidiary of Mabpharm Limited. Approved in China in May 2023, it is the first domestically produced therapeutic antibody for allergic asthma. CMAB007 is also undergoing Phase III clinical trials for chronic spontaneous urticaria in patients unresponsive to H1 antihistamines. As an omalizumab biosimilar, it targets IgE-mediated allergic diseases and has been included in China's national health insurance catalogue, facilitating widespread adoption across healthcare institutions. Currently, the drug is in Phase III stage of its development for the treatment of Chronic Urticaria.
* Povorcitinib - Incyte Corporation
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 3 clinical trials for hidradenitis suppurativa (HS) and vitiligo. A Phase 3 trial is being planned for prurigo nodularis (PN). Phase II studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase III clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.
* Briquilimab: Jasper Therapeutics
Briquilimab (JSP191) is an unconjugated, aglycosylated, anti-c-Kit antibody that functionally blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). The interaction of SCF and c-Kit is required for mast cells to survive. By blocking SCF from binding to c-Kit and disrupting the critical survival signal, briquilimab causes mast cells to undergo orderly cell death. For mast cell-driven diseases such as chronic urticaria, this removes the underlying source of the inflammatory response. In low-to-intermediate risk MDS, briquilimab blocks critical cell survival signals, depleting Kit-expressing MDS cells. For stem cell transplant, briquilimab blocks the ability of stem cells to recover from low intensity radiation, thereby opening the specific niches in the bone marrow for donor or gene-corrected hematopoietic stem cells to engraft. Currently, the drug is in Phase II stage of its development for the treatment of Chronic Urticaria.
The Chronic Urticaria Pipeline Report Provides Insights into-
* The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Urticaria with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Urticaria Treatment.
* Chronic Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Chronic Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Urticaria market
Explore groundbreaking therapies and clinical trials in the Chronic Urticaria Pipeline. Access DelveInsight's detailed report now! @ New Chronic Urticaria Drugs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Chronic Urticaria Companies
Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.
Chronic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Chronic Urticaria Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Chronic Urticaria Treatment. Learn about new drugs, Chronic Urticaria Pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Urticaria Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Chronic Urticaria Pipeline Report
* Coverage- Global
* Chronic Urticaria Companies- Synermore Biologics, Incyte Corporation, Jasper Therapeutics, Novartis, Regeneron/Sanofi, Principia Biopharma, Enanta Pharmaceuticals, Granular Therapeutics, Blueprint Medicines, Newave Pharmaceutical , and others.
* Chronic Urticaria Pipeline Therapies- Omalizumab (Xolair), BLU-808, AK002, Levocetirizine, Loratadine, Desloratadine, Povorcitinib, Bilastine , and others.
* Chronic Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Chronic Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Chronic Urticaria Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Urticaria Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/chronic-urticaria-or-hives-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Chronic Urticaria: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Chronic Urticaria - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* CMAB007: Taizhou Mabtech Pharmaceutical Co.,Ltd
* Mid Stage Products (Phase II)
* Povorcitinib - Incyte Corporation
* Early Stage Products (Phase I)
* Briquilimab: Jasper Therapeutics
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Chronic Urticaria Key Companies
* Chronic Urticaria Key Products
* Chronic Urticaria - Unmet Needs
* Chronic Urticaria - Market Drivers and Barriers
* Chronic Urticaria - Future Perspectives and Conclusion
* Chronic Urticaria Analyst Views
* Chronic Urticaria Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-urticaria-pipeline-appears-robust-with-20-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-urticaria-or-hives-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4093257 • Views: …
More Releases from ABNewswire
How Bedrock Restoration of Edina Fixes Basement Water Damage for Good
When water seeps into your basement, time is not on your side. Delays in cleanup only make the situation worse and more expensive to fix.
Dealing with basement water damage [https://bedrockrestoration.com/water-damage-restoration-edina-mn/#:~:text=BASEMENT%20WATER%20DAMAGE] is every Edina homeowner's nightmare. Whether it's a sudden flood or hidden leaks over time, moisture in your lower level can quickly lead to structural problems, mold growth, and ruined belongings. When your basement is under threat, it's crucial to…
PF&A Design Named Top Building Architect for Innovative Spaces
From hospitals and community centers to commercial developments and custom residential projects, PF&A Design has built a strong reputation as a local building architect dedicated to enhancing the Norfolk skyline.
When it comes to transforming ideas into award-winning structures, the right building architect [https://www.pfa-architect.com/#:~:text=Top%20healthcare-,architects,-creating%20modern%20facilities] can make all the difference. Many businesses and homeowners looking for a building architect near me have discovered that the true leaders in the field are the…
Dee Agarwal on Recognizing Industries That Are Ripe for Disruption
Dee Agarwal explores how to spot industries ripe for disruption by identifying inefficiencies, outdated assumptions, and cultural lag, urging innovators to look beyond technology and listen closely to what consumers and systems quietly reveal.
ATLANTA, GA - July 4th, 2025 - In the dynamic landscape of modern commerce, innovation is not a mere advantage; it is an existential necessity. Yet while some sectors evolve continuously, others linger in outdated paradigms, creating…
Avenue towards Advanced Dental Implants in Vasai - Rajeshwari Dental Clinic
Based in Palghar, Rajeshwari Dental Clinic is making substantial inroads to become a preferred centre for patients seeking a trusted dental clinic in Vasai, primarily specialising in dental implants in Vasai and All-on-Four dental implants in Vasai. The benchmark set in place for quality treatment in the region is the transparent costs, comprehensive services, and expert leadership.
An ever-growing healthcare corridor from Palghar to Vasai, the Rajeshwari Dental Clinic, has become…
More Releases for Chronic
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Reviewed, …
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017”, provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney Disease (Chronic Renal Failure). Report includes an overview of trial numbers and…
Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market Res …
Latest industry research report on: Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts
GlobalData's clinical trial report, Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H1, 2017" provides an overview of Chronic Kidney Disease (Chronic Renal Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Chronic Kidney…
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, T …
Orbisreserach.Com Adds “H1 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Market Pipeline Review 2017 Trend Analysis Report Report” To Its Research Database
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the…
Boot chronic pain
For immediate release
Due to our rushed lives and stressful environment, many people are suffering from chronic pain and fatigue.
We feel permanently tired and are barely able to get through our normal day. One is able to change this status when following the guidelines the book "Tired of being Tired to the point of being Gatvol (Fed Up). Some people will need a team of medical practitioners to help them…
Global Chronic, Acute, And Neuropathic Pain Market: Opioids To Remain Most Value …
The research report, titled “Frontier Pharma: Chronic, Acute And Neuropathic Pain - GPCR And Nerve Growth Factor-Based Therapies Offer Strong Potential In Difficult-To-Treat Subtypes,” analyzes the historical as well as the existing performance of this market, emphasizing specifically on various types of therapies applied to treat chronic, acute, and neuropathic pain.
According to this 68-page study, the worldwide market for chronic, acute, and neuropathic pain has been observing a significant…
Targeting chronic pain
With the support of the Austrian Science Fund FWF, the neurophysiologist Ruth Drdla-Schutting is investigating the role astrocytes play in the genesis of chronic pain. With the help of innovative gene technology (DREADDs), scientists are tailoring treatment specifically to these cells that are the most numerous found in the central nervous system.
Pain is an important protection system of the human body. But when it becomes chronic, as it frequently…
